PDCD1 and acute kidney injury: Apart from anti-PD-1 plus anti-CTLA-4, anti-PD-L1 plus anti-CTLA-4, anti-PD-L1 plus targeted therapy, and targeted therapy, all other treatment regimens showed increased risk of grade 3-5 AKI compared with placebo.